Online Virtual Scientific Program News Today

Amgen today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial. The trial evaluated bemarituzumab plus chemotherapy versus chemotherapy alone in patients with FGFR2b-positive, HER2-negative frontline advanced gastric or gastroesophageal junction cancers . New data includes median overall survival a secondary endpoint that was reached with longer ...

Amgen today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b overexpressing and human epidermal growth factor receptor 2 -negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma in combination with modified FOLFOX6 based on … – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration ...